Reported 1 day ago
Regeneron Pharmaceuticals, a biotech leader, has seen its stock plummet by 30% mainly due to challenges with its Eylea drug, but the company remains a strong long-term investment. With robust sales from Dupixent and promising new gene therapies in development, Regeneron is positioned to recover. Additionally, the initiation of a quarterly dividend of $0.88 and a stock buyback program signal a commitment to returning value to shareholders, making it an attractive buy for the next decade.
Source: YAHOO